Clinical trial
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute…
NCT00093990 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00093990 |
|---|---|
| Title | Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) |
| Official title | A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or Older (Farnesyl Transferase Inhibition Global Human Trials AML 301 [F.I.G.H.T. AML 301]) |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Tipifarnib, Zarnestra, R115777 |
| Enrollment | 457 |
| Start date | Jan 1, 2004 |
| Completion | Oct 1, 2007 |
| First posted | Oct 11, 2004 |
| Last update posted | Sep 14, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: